Osimertinib Receives Breakthrough Therapy Designation for NSCLC in First-Line

October 9, 2017 – The FDA has awarded Breakthrough Therapy Designation to osimertinib for first-line treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib is a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI) designed to inhibit both EGFR-sensitizing and EGFR T790M-resistance mutations, with clinical activity against central nervous system (CNS) metastases. Frontline osimertinib was associated with … (leggi tutto)